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Purpose: In breast cancer patients who do not undergo surgery 
due to metastatic disease or severe medical comorbidities, the 
unresected primary tumour may cause symptoms such as pain, 
skin ulceration and bleeding. Hypofractionated partial breast 
irradiation (HPBI) is a treatment modality aimed at achieving 
local control (LC) and reducing symptom burden while 
minimizing the duration of radiation treatments 
Methods and Materials: This retrospective review included all 
patients treated with HPBI for unresected breast tumours at a 
large tertiary cancer centre between August 2013 and December 
2015. Primary outcome measures were LC (no progression of 
disease after treatment) and feasibility (no discontinuation of 
HPBI due to acute toxicity). Secondary outcomes included: 
response (categorized as complete, > 50%, or < 50%), change in 
symptoms, and acute toxicities. 
Results: Twenty patients (22 breast tumours) were evaluated. 
Median age was 83 (range: 46-100). Thirteen of 22 (59%) breast 
tumours were ER/PR positive and 60% of patients had prior 
endocrine therapy for a median duration of 10 months (range: 1-
40). Eleven patients had comorbidities precluding surgery, seven 
had metastatic disease, and two declined surgery. Eleven 
patients (55%) presented with skin ulceration, four (20%) with 
substantial bleeding requiring dressing changes, and six (30%) 
with pain not adequately controlled with analgesics. Average 
size of the primary lesion was 6.1 cm (range: 2-14). HPBI was 
delivered as 5 fractions given once or twice per week; the 
prescribed dose was 35-40 Gy to the primary lesion, 25-35 Gy to 
the axilla, and 25 Gy to the supraclavicular fossa/whole breast, 
as indicated. Eighteen (90%) patients completed HPBI and 2 
stopped after 1 fraction (though not due to toxicity). Acute 
Grade 1 (RTOG scale) skin toxicity was seen in 12 patients and 
Grade 2 or 3 toxicity with moist desquamation in seven patients 
(no Grade 4 toxicities). Average follow up was 6.4 months (range: 
1-23). At three months follow up (n = 19), all had LC, with 16% 
having a complete response (CR), 37% a > 50% response, and 47% 
a < 50% response. Bleeding resolved in all and skin ulceration had 
a CR in 22% and partial response in 78%. At one year follow up (n 
= 10), nine had LC and one had progression (this patient declined 
completing HPBI after 1 fraction). CR was seen in 30%, > 50% 
response in 40%, and < 50% response in 10%. Skin ulceration had 
a CR in all five patients with documentation at this time point. 
One patient had 23 months follow up and had LC with complete 
resolution of symptoms. 
Conclusions: HPBI is a feasible treatment modality for LABC and 
is effective at achieving LC and reducing symptoms in the 
context of patients with metastatic disease or comorbidities 
precluding surgery. Longer follow up and prospective research is 
needed to further assess this approach. 
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Purpose: Conventionally fractionated adjuvant radiation therapy 
(RT) for invasive breast carcinomas and ductal carcinoma in situ 
(DCIS), has resulted in 10-year local recurrence rates of less than 
10%. Although the oncologic outcomes using hypofractionated RT 
(HF) for early invasive breast carcinoma is equivalent to 
conventional fractionation, there is no randomized trial 
published in the context of DCIS. This study aims at examining 
the Disease-Free Survival (DFS) of DCIS following HF in order to 
identify a population at high-risk (five-year DFS < 90%) of 
recurrence. 
Methods and Materials: Women with DCIS that were treated with 
surgery and HF at 3 Canadian and 2 Australian tertiary RT 
departments were identified. The median dose of HF was 42.5 
Gy (31.2-46.0) in 2.5-2.66 Gy per fraction. Treatment and 
outcomes were assessed through administrative databases and 
validated by chart review. Kaplan-Meier was used to estimate 
the DFS. Univariate and multivariate analyses were performed to 
examine the association between various pathological and 
treatment related factors and DFS. Competing risk analysis and 
Gray’s test were performed to determine the association of 
various risk factors with breast related events. 
Results: There were 600 women identified. Boost RT was 
administered to 224 (37.3%) patients. The median age was 66 
(42-86) years old. The median tumour size was 0.90 cm (0.1-6.3). 
Grade 3 DCIS was found in 30.6%. Surgical margins were ≤ 3 mm 
or positive in 35.8% and 3.8%, respectively. ER status was positive 
in 85.0% and adjuvant hormonal therapy was given to 57.5% of 
the patients. The median follow up was 5.4 years (0.2-11.5). The 
five-year DFS of all patients was 92.1%. On univariate analysis, 
tumour size, ER status, presence of tumour necrosis, and use of 
adjuvant hormonal therapy were not correlated with a worsened 
DFS. Grade 3 tumours and positive surgical margins were 
significantly (p < 0.0001 and p = 0.006) associated with shorter 
DFS. There were too few patients of age < 45 (n = 8) or with HER2 
known status (n = 62) for analysis. On multivariate analysis, 
Grade 3 (versus Grade 1-2 HR = 2.53 (95% Confidence Interval 
(CI): 1.46-4.36), p = 0.0009) and positive margins (versus 
negative HR = 3.05 (95%CI: 1.30-7.19), p = 0.0106) significantly 
worsened DFS, with five-year DFS of 87.9% and 78.0% 
respectively. Competing risk analysis suggested that there was a 
trend (p = 0.09) for positive surgical margins to be associated 
with increased breast related events. Grade 3 DCIS significantly 
(p = 0.0004) recurred more often than Grade 1-2 tumours. 
Conclusions: DCIS patients who received HF had DFS that is 
comparable to published results from conventional RT. Patients 
who have positive surgical margins and Grade 3 tumours are at 
higher risk of breast events after HF. Our future work will include 
a retrospective non-inferiority assessment of the efficacy of HF 
versus conventional RT in high-risk DCIS patients from the same 
institutions. 
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Purpose: To assess acute toxicities and clinical outcomes of 
craniospinal irradiation (CSI) delivered using Helical 
Tomotherapy (HT).  
Methods and Materials: We conducted a retrospective review of 
patients treated with HT CSI at the McGill University Health 
Centre between 2007 and 2015. In total, 45 patients with varying 
primary diagnoses including 22 (49%) with medulloblastoma, 
were analyzed. Median age was 18 years (3-46). Median CSI dose 
was 36 Gy (12-39.6) in 20 fractions (6-22), in both children and 
adults. A boost to the tumour bed or posterior fossa to a median 
dose of 19.8 Gy (6-32.4) was given in 80% of patients. Eighty-
three percent of patients received chemotherapy, with regimens 
varying according to histology. Kaplan-Meier curves were used 
for estimation of progression-free survival (PFS) and overall 
survival (OS). 
Results: Median follow up was 21 months (1-97). Ninety-five 
percent of children versus 71% of adults received chemotherapy 
(p = 0.03). There was a 24% (-5-47%), 53% (range = -124-87%), and 
69% (-55-94%) decrease in white blood cells, haemoglobin and 
platelets at nadir compared to baseline, with no statistically 
significant difference between children and adults. In total, 27% 
of pediatric patients and 25% of adults developed Grade ≥ 3 
cytopenia. Grade ≥ 1 nausea/vomiting occurred in 45% of 
children and 58% of young adults (p > 0.1); and Grade ≥ 2 
anorexia occurred in 27% and 13%, respectively. Mean percent 
weight loss over CSI course was 6% in children and 4% in adults. 
Four patients (9%) required nutritional support with nasogastric 
or percutaneous endoscopic gastrostomy tubes. Mean dose to the 
